Results 31 to 40 of about 6,192 (194)
Biomedicines, 2023 The repurposing of drugs is one of the most competent strategies for discovering new antimicrobial agents. Vildagliptin is a dipeptidyl peptidase-4 inhibitor (DPI-4) that is used effectively in combination with metformin to control blood glucose levels ...
Maan T. Khayat +7 more
doaj +1 more source
Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
, 2020 Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus.
Magdalena Nowaczewska +5 more
core +1 more source
Tip 2 diyabet hastalarında vildagliptin tedavisinin portal ven basıncı ve hepatosteatoz üzerine etkisi [PDF]
, 2018 Objective: ftis study investigated how vildagliptin (a di-pepti- dyl peptidase 4 inhibitor) affects portal vein pressure and hepat- osteatosis in patients with type 2 diabetes mellitus.
Çakırca, Mustafa +21 more
core +1 more source
Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients
Frontiers in Endocrinology, 2021 Background and aimsAnimal studies suggested that vildagliptin might exert a beneficial effect on cognitive function. The present study evaluated whether the use of vildagliptin in patients with type 2 diabetes mellitus might affect dementia risk ...
Chin-Hsiao Tseng +2 more
doaj +1 more source
ELECTROPHORESIS, EarlyView.Cyclodextrins are the most often applied chiral selectors in CE enantioseparations. In combination with NMR spectroscopy and molecular modeling, studies for an understanding of chiral recognition underlying enantioseparations have been performed.
Gerhard K. E. Scriba
wiley +1 more source
Cardiovascular Diabetology, 2011 Background Progressive remodeling after myocardial infarction (MI) is a leading cause of morbidity and mortality. Recently, glucagon-like peptide (GLP)-1 was shown to have cardioprotective effects, but treatment with GLP-1 is limited by its short half ...
van Gilst Wiek H +4 more
doaj +1 more source
Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries
British Journal of Pharmacology, EarlyView.Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims We evaluated the risk of mental health disorders among glucagon‐like peptide‐1 receptor agonist (GLP1RA) users compared with users of dipeptidyl peptidase‐4 (DPP‐4) inhibitors and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. Materials and Methods We conducted a nationwide, active‐comparator new‐user cohort study using the Korean ...
Chungsoo Kim +5 more
wiley +1 more source
Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man
Frontiers in Endocrinology, 2019 Vildagliptin blocks glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) inactivation of the meal induced increases in GLP-1 and GIP so that elevated GLP-1 and GIP levels are maintained over 24 h.
James E. Foley
doaj +1 more source
Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats. [PDF]
PLoS ONE, 2014 BACKGROUND: Obese-insulin resistance caused by long-term high-fat diet (HFD) consumption is associated with left ventricular (LV) dysfunction and increased risk of myocardial infarction.
Nattayaporn Apaijai +4 more
doaj +1 more source